Skip to main content
Contact Locations Diversity Pro Bono Why Wolf
Nathan T. Jacobs

Nathan T. Jacobs, PhD

(he/him/his)
Associate | Biotechnology
617.646.8557 Nathan.Jacobs@WolfGreenfield.com LinkedIn Profile

Education

  • BS, Immunology & Infectious Disease, The Pennsylvania State University, with honors
  • BS, Biology, The Pennsylvania State University
  • PhD, Biological and Biomedical Sciences, Emory University
  • JD, Suffolk University Law School, cum laude 

Key Technologies

  • Virology
  • Microbiology
  • Genetically Modified Organisms
  • Biomanufacturing
  • Vaccines
  • Immunology
  • Nucleic Acid Production & Purification
  • Cell Therapy
  • Gene Therapy
  • Antibodies

Practice Groups

Admitted to Practice

  • Massachusetts
  • US Patent and Trademark Office

Location

  • Boston

Overview

Nate Jacobs’s practice focuses on the preparation and prosecution of US and foreign patent applications in the life sciences, and strategic portfolio counseling including due diligence, freedom-to-operate analyses, and trade secret evaluation. He regularly advises innovators in microbiology, virology, and immunology, working with clients ranging from early-stage start-ups to publicly traded biotechnology companies.

Nate’s IP experience is particularly focused in the areas of live biotherapeutic products, genetically modified organisms (including bacteria, viruses, fungi, and mammals), biomanufacturing and fermentation processes, biologics manufacturing and purification, T cell therapies, vaccines, and gene delivery vectors. This legal experience rests on a foundation of 10 years of research experience in the ecology and evolution of respiratory pathogens including influenza viruses, Streptococcus pneumoniae, and Bordetella bronchiseptica. This background equips Nate to fully grasp the intricacies of bacteria-, virus-, and host-centered technologies and craft legal strategies that account for the realities of organismal biology and the evolving nature of biological systems.

As a PhD student, Nate assisted the Emory Patent Group with prior art searching, evaluating invention disclosures, and application drafting and prosecution for inventions by Emory researchers.

Experience

  • Developed and managed global patent portfolios protecting clinical candidates in live biotherapeutic products, vaccines, and T cell therapies, including formulations and manufacturing methods, for infectious disease, autoimmune disease, and cancer
  • Developed and implemented portfolio strategies addressing evolutionary biology issues in organism-centered technologies
  • Advised clients on regulatory exclusivity-focused portfolio management accounting for double patenting, Patent Term Adjustment (PTA), and Patent Term Extension (PTE) considerations
  • Counseled clients on IP diligence for clinical and preclinical assets being considered for acquisition
  • Counseled clients on third-party risks including competitive IP landscape and infringement

Activities

  • Boston Intellectual Property Law Association

Recognition

  • Jurisprudence Awards in Land Use Law; Evidence; and Trademark Law, Suffolk University Law School
  • Trustee Academic Scholarship, Suffolk University Law School (2021–2025)
  • Infectious Diseases and Basic Microbiological Mechanisms T32 Postdoctoral Fellow, National Institute of Allergy and Infectious Diseases to NYU Langone Health (2019–2020)
  • Molecules to Mankind Fellowship, Burroughs Wellcome Fund (2016–2018)
  • Graduate Research Fellowship Program Honorable Mention, National Science Foundation (2015)
  • Barry M. Goldwater Scholarship (2012)

Publications

Scientific Publications

  • Jacobs NT, Onuoha NO, Antia A, Steel J, Antia R, Lowen AC. (2019). Incomplete influenza A virus genomes occur frequently but are readily complemented during localized viral spread. Nat Commun. 10(1):3526.
  • Jacobs NT, Weiser JN. (2020). Competitive exclusion strengthens selection for transmissibility and increases the benefit of recombination for within-host adaptation. bioRxiv. doi: 10.1101/2020.06.18.158956.
  • Wu X*, Jacobs NT*, Bozio C, Palm P, Lattar SM, Hanke CR, Watson DM, Sakai F, Levin BR, Klugman KP, Vidal JE. (2017). Competitive Dominance within Biofilm Consortia Regulates the Relative Distribution of Pneumococcal Nasopharyngeal Density. Appl Environ Microbiol. 83(16):e00953-17. *Equal contribution.
  • Aggarwal SD, Lees JA, Jacobs NT, Bee GCW, Abruzzo AR, Weiser JN. (2023). BlpC-mediated selfish program leads to rapid loss of Streptococcus pneumoniae clonal diversity during infection. Cell Host Microbe. 31(1):124-134.e5
  • Hockman MR, Jacobs NT, Mainou BA, Koelle K, Lowen AC. (2022). Mammalian Orthoreovirus Proceeds with Little Constraint on Segment Mixing. J Virol. 96(4):e0183221.
  • Phipps KL, Ganti K, Jacobs NT, Lee CY, Carnaccini S, White MC, Manandhar M, Pickett BE, Tan GS, Ferreri LM, Perez DR, Lowen AC. (2020). Collective interactions augment influenza A virus replication in a host-dependent manner. Nat Microbiol. doi: 10.1038/s41564-020-0749-2.
  • Calderon BM, Danzy S, Delima GK, Jacobs NT, Ganti K, Hockman MR, Conn GL, Lowen AC, Steel J. (2019). Dysregulation of M segment gene expression contributes to influenza A virus host restriction. PLoS Pathog. 15(8):e1007892.
  • Richard M, Herfst S, Tao H, Jacobs NT, Lowen AC. (2018). Influenza A Virus Reassortment Is Limited by Anatomical Compartmentalization following Coinfection via Distinct Routes. J Virol. 92(5):e02063-17.
  • Matar CG, Jacobs NT, Speck SH, Lamb TJ, Moormann AM. (2015). Does EBV alter the pathogenesis of malaria? Parasite Immunol. 37(9):433-45.
  • Matar CG, Anthony NR, O'Flaherty BM, Jacobs NT, Priyamvada L, Engwerda CR, Speck SH, Lamb TJ. (2015). Gammaherpesvirus Co-infection with Malaria Suppresses Anti-parasitic Humoral Immunity. PLoS Pathog. 11(5):e1004858.
  • Smallridge WE, Rolin OY, Jacobs NT, Harvill ET. (2014). Different effects of whole-cell and acellular vaccines on Bordetella transmission. J Infect Dis. 209(12):1981-8.

Interests

  • Cooking
  • Photography
  • Board Games 
Top